Cargando…

Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation

Proprotein convertase subtilisin/kexin type 9 (PCSK9), beyond regulating LDL cholesterol (LDL-c) plasma levels, exerts several pleiotropic effects by modulating lipid metabolism in extrahepatic cells such as macrophages. Macrophage cholesterol homeostasis depends on serum lipoprotein functions, incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Palumbo, Marcella, Giammanco, Antonina, Purrello, Francesco, Pavanello, Chiara, Mombelli, Giuliana, Di Pino, Antonino, Piro, Salvatore, Cefalù, Angelo Baldassare, Calabresi, Laura, Averna, Maurizio, Bernini, Franco, Zimetti, Francesca, Adorni, Maria Pia, Scicali, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343790/
https://www.ncbi.nlm.nih.gov/pubmed/35928226
http://dx.doi.org/10.3389/fmolb.2022.925587
_version_ 1784761068852084736
author Palumbo, Marcella
Giammanco, Antonina
Purrello, Francesco
Pavanello, Chiara
Mombelli, Giuliana
Di Pino, Antonino
Piro, Salvatore
Cefalù, Angelo Baldassare
Calabresi, Laura
Averna, Maurizio
Bernini, Franco
Zimetti, Francesca
Adorni, Maria Pia
Scicali, Roberto
author_facet Palumbo, Marcella
Giammanco, Antonina
Purrello, Francesco
Pavanello, Chiara
Mombelli, Giuliana
Di Pino, Antonino
Piro, Salvatore
Cefalù, Angelo Baldassare
Calabresi, Laura
Averna, Maurizio
Bernini, Franco
Zimetti, Francesca
Adorni, Maria Pia
Scicali, Roberto
author_sort Palumbo, Marcella
collection PubMed
description Proprotein convertase subtilisin/kexin type 9 (PCSK9), beyond regulating LDL cholesterol (LDL-c) plasma levels, exerts several pleiotropic effects by modulating lipid metabolism in extrahepatic cells such as macrophages. Macrophage cholesterol homeostasis depends on serum lipoprotein functions, including the HDL capacity to promote cell cholesterol efflux (CEC) and the serum capacity to promote cell cholesterol loading (CLC). The aim of this observational study was to investigate the effect of PCSK9 inhibitors (PCSK9-i) treatment on HDL-CEC and serum CLC in patients with familial hypercholesterolemia (FH). 31 genetically confirmed FH patients were recruited. Blood was collected and serum isolated at baseline and after 6 months of PCSK9-i treatment. HDL-CEC was evaluated through the main pathways with a radioisotopic cell-based assay. Serum CLC was assessed fluorimetrically in human THP-1 monocyte-derived macrophages. After treatment with PCSK9-i, total cholesterol and LDL-c significantly decreased (−41.6%, p < 0.0001 and −56.7%, p < 0.0001, respectively). Total HDL-CEC was not different between patients before and after treatment. Conversely, despite no changes in HDL-c levels between the groups, ABCG1 HDL-CEC significantly increased after treatment (+22.2%, p < 0.0001) as well as HDL-CEC by aqueous diffusion (+7.8%, p = 0.0008). Only a trend towards reduction of ABCA1 HDL-CEC was observed after treatment. PCSK9-i significantly decreased serum CLC (−6.6%, p = 0.0272). This effect was only partly related to the reduction of LDL-c levels. In conclusion, PCSK9-i treatment significantly increased HDL-CEC through ABCG1 and aqueous diffusion pathways and reduced the serum CLC in FH patients. The favorable effect of PCSK9-i on functional lipid profile could contribute to the cardiovascular benefit of these drugs in FH patients.
format Online
Article
Text
id pubmed-9343790
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93437902022-08-03 Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation Palumbo, Marcella Giammanco, Antonina Purrello, Francesco Pavanello, Chiara Mombelli, Giuliana Di Pino, Antonino Piro, Salvatore Cefalù, Angelo Baldassare Calabresi, Laura Averna, Maurizio Bernini, Franco Zimetti, Francesca Adorni, Maria Pia Scicali, Roberto Front Mol Biosci Molecular Biosciences Proprotein convertase subtilisin/kexin type 9 (PCSK9), beyond regulating LDL cholesterol (LDL-c) plasma levels, exerts several pleiotropic effects by modulating lipid metabolism in extrahepatic cells such as macrophages. Macrophage cholesterol homeostasis depends on serum lipoprotein functions, including the HDL capacity to promote cell cholesterol efflux (CEC) and the serum capacity to promote cell cholesterol loading (CLC). The aim of this observational study was to investigate the effect of PCSK9 inhibitors (PCSK9-i) treatment on HDL-CEC and serum CLC in patients with familial hypercholesterolemia (FH). 31 genetically confirmed FH patients were recruited. Blood was collected and serum isolated at baseline and after 6 months of PCSK9-i treatment. HDL-CEC was evaluated through the main pathways with a radioisotopic cell-based assay. Serum CLC was assessed fluorimetrically in human THP-1 monocyte-derived macrophages. After treatment with PCSK9-i, total cholesterol and LDL-c significantly decreased (−41.6%, p < 0.0001 and −56.7%, p < 0.0001, respectively). Total HDL-CEC was not different between patients before and after treatment. Conversely, despite no changes in HDL-c levels between the groups, ABCG1 HDL-CEC significantly increased after treatment (+22.2%, p < 0.0001) as well as HDL-CEC by aqueous diffusion (+7.8%, p = 0.0008). Only a trend towards reduction of ABCA1 HDL-CEC was observed after treatment. PCSK9-i significantly decreased serum CLC (−6.6%, p = 0.0272). This effect was only partly related to the reduction of LDL-c levels. In conclusion, PCSK9-i treatment significantly increased HDL-CEC through ABCG1 and aqueous diffusion pathways and reduced the serum CLC in FH patients. The favorable effect of PCSK9-i on functional lipid profile could contribute to the cardiovascular benefit of these drugs in FH patients. Frontiers Media S.A. 2022-07-19 /pmc/articles/PMC9343790/ /pubmed/35928226 http://dx.doi.org/10.3389/fmolb.2022.925587 Text en Copyright © 2022 Palumbo, Giammanco, Purrello, Pavanello, Mombelli, Di Pino, Piro, Cefalù, Calabresi, Averna, Bernini, Zimetti, Adorni and Scicali. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Palumbo, Marcella
Giammanco, Antonina
Purrello, Francesco
Pavanello, Chiara
Mombelli, Giuliana
Di Pino, Antonino
Piro, Salvatore
Cefalù, Angelo Baldassare
Calabresi, Laura
Averna, Maurizio
Bernini, Franco
Zimetti, Francesca
Adorni, Maria Pia
Scicali, Roberto
Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
title Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
title_full Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
title_fullStr Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
title_full_unstemmed Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
title_short Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
title_sort effects of pcsk9 inhibitors on hdl cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343790/
https://www.ncbi.nlm.nih.gov/pubmed/35928226
http://dx.doi.org/10.3389/fmolb.2022.925587
work_keys_str_mv AT palumbomarcella effectsofpcsk9inhibitorsonhdlcholesteroleffluxandserumcholesterolloadingcapacityinfamilialhypercholesterolemiasubjectsamultilipidcenterrealworldevaluation
AT giammancoantonina effectsofpcsk9inhibitorsonhdlcholesteroleffluxandserumcholesterolloadingcapacityinfamilialhypercholesterolemiasubjectsamultilipidcenterrealworldevaluation
AT purrellofrancesco effectsofpcsk9inhibitorsonhdlcholesteroleffluxandserumcholesterolloadingcapacityinfamilialhypercholesterolemiasubjectsamultilipidcenterrealworldevaluation
AT pavanellochiara effectsofpcsk9inhibitorsonhdlcholesteroleffluxandserumcholesterolloadingcapacityinfamilialhypercholesterolemiasubjectsamultilipidcenterrealworldevaluation
AT mombelligiuliana effectsofpcsk9inhibitorsonhdlcholesteroleffluxandserumcholesterolloadingcapacityinfamilialhypercholesterolemiasubjectsamultilipidcenterrealworldevaluation
AT dipinoantonino effectsofpcsk9inhibitorsonhdlcholesteroleffluxandserumcholesterolloadingcapacityinfamilialhypercholesterolemiasubjectsamultilipidcenterrealworldevaluation
AT pirosalvatore effectsofpcsk9inhibitorsonhdlcholesteroleffluxandserumcholesterolloadingcapacityinfamilialhypercholesterolemiasubjectsamultilipidcenterrealworldevaluation
AT cefaluangelobaldassare effectsofpcsk9inhibitorsonhdlcholesteroleffluxandserumcholesterolloadingcapacityinfamilialhypercholesterolemiasubjectsamultilipidcenterrealworldevaluation
AT calabresilaura effectsofpcsk9inhibitorsonhdlcholesteroleffluxandserumcholesterolloadingcapacityinfamilialhypercholesterolemiasubjectsamultilipidcenterrealworldevaluation
AT avernamaurizio effectsofpcsk9inhibitorsonhdlcholesteroleffluxandserumcholesterolloadingcapacityinfamilialhypercholesterolemiasubjectsamultilipidcenterrealworldevaluation
AT berninifranco effectsofpcsk9inhibitorsonhdlcholesteroleffluxandserumcholesterolloadingcapacityinfamilialhypercholesterolemiasubjectsamultilipidcenterrealworldevaluation
AT zimettifrancesca effectsofpcsk9inhibitorsonhdlcholesteroleffluxandserumcholesterolloadingcapacityinfamilialhypercholesterolemiasubjectsamultilipidcenterrealworldevaluation
AT adornimariapia effectsofpcsk9inhibitorsonhdlcholesteroleffluxandserumcholesterolloadingcapacityinfamilialhypercholesterolemiasubjectsamultilipidcenterrealworldevaluation
AT scicaliroberto effectsofpcsk9inhibitorsonhdlcholesteroleffluxandserumcholesterolloadingcapacityinfamilialhypercholesterolemiasubjectsamultilipidcenterrealworldevaluation